Aliqopa

Generic name: Copanlisib
Drug class: PI3K inhibitors

Usage of Aliqopa

Aliqopa is a cancer medicine that works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

Aliqopa injection is used to treat people with follicular lymphoma (a slow-growing blood cancer) that has returned after after treatment with at least two other medicines.

Aliqopa belongs to a class of medications called kinase inhibitors.

Aliqopa side effects

Get emergency medical help if you have signs of an allergic reaction to Aliqopa (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).

Aliqopa may cause serious side effects. Call your doctor at once if you have:

a new or worsening cough, chest pain, or trouble breathing;

severe skin redness, itching, or swelling;

signs of infection - fever, chills, sore throat, body aches, unusual tiredness, loss of appetite, bruising or bleeding;

high blood sugar - increased thirst, increased urination, dry mouth, fruity breath odor;

increased blood pressure - severe headache, pounding in your neck or ears, dizziness, or feeling like you might pass out; or

low white blood cell counts - fever, mouth sores, skin sores, sore throat, cough.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common Aliqopa side effects may include:

low blood cell counts;

high blood pressure;

high blood sugar;

feeling weak or tired;

nausea, diarrhea; or

new or worsening cough, fever, trouble breathing.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Aliqopa

To make sure Aliqopa is safe for you, tell your doctor if you have ever had:

low white blood cell counts;

an infection;

lung disease or breathing problems;

high blood pressure;

diabetes (Aliqopa can raise your blood sugar); or

liver disease.

You may need to have a negative pregnancy test before starting this treatment.

Both men and women using Aliqopa should use effective birth control to prevent pregnancy. Copanlisib can harm an unborn baby if the mother or father is using this medicine.

Keep using birth control for at least 1 months after your last dose. Tell your doctor right away if a pregnancy occurs.

Do not breastfeed while using Aliqopa, and for at least 1 month after your last dose.

Relate drugs

How to use Aliqopa

Usual Adult Dose for Follicular Lymphoma:

60 mg via 1-hour IV infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3 weeks on and 1 week off). Duration of Therapy: Until disease progression or unacceptable toxicity Comments: Accelerated approval was granted based on overall response rate; continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. Use: Treatment of relapsed follicular lymphoma (FL) in patients who have received at least 2 prior systemic therapies.

Warnings

Tell your doctor and pharmacist if you are allergic to copanlisib, any other medications, or any of the ingredients in Aliqopa injection.

You may get infections more easily during treatment with Aliqopa. Serious and sometimes fatal infections may occur. Call your doctor if you have flu symptoms, cough, night sweats, neck stiffness, confusion, or vision problems.

What other drugs will affect Aliqopa

Sometimes it is not safe to use certain medicines at the same time. Some drugs can affect your blood levels of other drugs you use, which may increase side effects or make the medicines less effective.

This list is not complete and many other drugs may interact with copanlisib. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Popular FAQ

Aliqopa is a phosphatidylinositol-3-kinase (PI3K) inhibitor (kinase inhibitor). It is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least 2 prior treatments. Follicular lymphoma is a slow-growing type of B-cell non-Hodgkin lymphoma, a cancer of the lymph system. Aliqopa works by blocking several enzymes that promote cancer cell growth.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.